glp-1 weight loss muscle preservation Loss, Preservation, Sleep and the Future of Women's Metabolic Health How to Prevent Muscle Loss

[DOI] [PMC free article] [PubMed] [Google Scholar] 129.Chen J, Lin A, Luo P

The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI

References 1 AustinJ.KimbleJ

In Their Words Thanigavelan Jambulingam, PhD Professor of Food, Pharma and Healthcare What changes do you hope to see in the way that GLP-1 medications are manufactured or handled

Incretin-based therapies in obesity-related kidney disease In recent years, studies have been expanded to investigate the effects of incretin-based therapies on kidney outcomes in overweight/obese individuals without T2D

Ammar RA, Mohamed AF, Kamal MM, Safar MM, Abdelkader NF